July 26th 2024
A user-friendly “nudge” may provide a timely reminder to surgeons to consider the value of sentinel lymph node biopsy in older patients with breast cancer.
Community Practice Connections™: 14th Annual International Symposium on Ovarian Cancer and Other Gynecologic Malignancies
View More
Community Practice Connections™: The Advent of TROP2-Targeted Treatment Approaches in HR+/HER2- Breast Cancer
View More
Cancer Summaries and Commentaries™: Clinical Updates from Chicago in Breast Cancer
View More
Show Me the Data™: Do We Have Sea Change for Novel Approaches in HR+/HER2- Breast Cancer? CDK, PI3K/AKT, ADC, and Next-Gen SERD Strategies Assessed
View More
Community Practice Connections™: Controversies and Conversations About HER2- Expressing Breast Cancer…Advances in Management of HER2-Low to -Positive Disease
View More
42nd Annual CFS®: Innovative Cancer Therapy for Tomorrow®
November 13-15, 2024
Register Now!
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
42nd Annual Miami Breast Cancer Conference®
March 6 - 9, 2025
Register Now!
The Evolving Tool Box in Advanced HR+/HER2– Breast Cancer: What You Need to Know About Next-Generation SERDs, PI3K/AKT, ADCs, CDK4/6 and Beyond…
View More
Coffee Talk™: Navigating the Impact of HER2/3, TROP2, and PARP from Early Stage to Advanced Breast Cancer Care
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Ribociclib/Aromatase Inhibitors Maintain HRQOL in HR+, HER2– Breast Cancer
September 22nd 2023A health-related quality of life analysis of the phase 3 NATALEE trial supports the risk/benefit profile of adding ribociclib to nonsteroidal aromatase inhibitors in patients with hormone receptor–positive, HER2-negative early breast cancer.
Elacestrant Earns EU Approval for ESR1+, ER+, HER2– Advanced Breast Cancer
September 22nd 2023The regulatory decision to approve elacestrant in European patients with estrogen receptor–positive, HER2-negative locally advanced or metastatic breast cancer and an activating ESR1 mutation was based on data from the phase 3 EMERALD study.
Neratinib Combo Yields Meaningful Benefit in HR+ HER2-Mutant Breast Cancer
September 18th 2023Responses in patients with hormone receptor–positive, HER2-mutated breast cancer who crossed over to receive neratinib plus fulvestrant and trastuzumab support the necessity of neratinib in the triplet regimen.
Diet and Exercise Intervention Associated With Better pCR in TNBC or HR+, HER2– BC
September 6th 2023Despite seeming to elicit more pathological complete responses in patients with hormone receptor–positive, HER2-negative triple-negative breast cancer receiving neoadjuvant chemotherapy, diet and exercise did not affect relative dose intensity.